Genes predict GLP‑1 response

These drugs copy gut hormones that tell your brain you’ve eaten enough, so people taking semaglutide or tirzepatide often feel full sooner and eat less. Semaglutide mainly mimics glucagon-like peptide 1, while tirzepatide hits both glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide, which is why the two medicines do not act in exactly the same way. (nature.com) The puzzle is that two people can take the same shot at the same dose and get very different results. Some patients lose less than 5% of body weight, while others lose more than 20%, and nausea or vomiting can be mild for one person and severe for another. (euronews.com) A gene is like an instruction sheet for building one tiny part of the body’s machinery. If the instruction sheet has a small spelling change, the finished part can still work, but it may react a little differently when a drug shows up. (nature.com) That is what researchers tested in a genome-wide association study, which is a giant comparison of DNA across many people looking for patterns. The team analyzed 27,885 people who reported using glucagon-like peptide 1 receptor agonist drugs and compared their genetics with reported weight loss and stomach side effects. (nature.com) The clearest signal showed up in GLP1R, the gene that makes the receptor semaglutide is designed to press like a doorbell. A missense variant in GLP1R was linked to greater weight loss, with about 0.76 kilograms of extra loss expected for each copy of the effect allele. (nature.com) The side-effect signal pointed to the same pathway but a different outcome. Variants in GLP1R were linked to nausea, and the study also found a signal in GIPR, the gene for the second receptor targeted by tirzepatide. (nature.com; pharmexec.com) That GIPR finding mattered most for tirzepatide users because tirzepatide activates the glucose-dependent insulinotropic polypeptide receptor and semaglutide does not. In the analysis, the GIPR association with vomiting appeared tirzepatide-specific, which fits the way the drug is built. (nature.com; pharmexec.com) This does not mean doctors can swab your cheek next week and know exactly how many pounds you will lose. The genetic effects in the paper were modest, and weight loss still depends on dose, time on treatment, other illnesses, and what people can tolerate long enough to keep taking. (reuters.com; nature.com) What the study does offer is a first draft of a sorting tool. If later studies confirm these markers, doctors could eventually use DNA the way oncologists use tumor markers now: not to pick a miracle, but to avoid a mismatch between a patient and a drug. (nature.com; 23andme.com) The bigger shift is that obesity treatment may start looking more like tailored medicine than one-size-fits-all prescribing. A field that already knows these drugs work on average is now starting to map who gets the biggest payoff, who gets the roughest side effects, and why those two groups are not always the same people. (euronews.com; nature.com)